Micro RNA
MicroRNAs constitute a recently discovered class of non-coding RNAs that play key roles in the regulation of gene expression. According to the International Agency for Research on Cancer (IARC), a specialized agency of the WHO, about 12.7 million new cancer cases were reported in 2008 and the number reached 14.1 million in 2012. MicroRNAs are used as a biomarker for cancer diagnosis and treatment. Some of the major companies operating in the global microRNA market are Affymetrix Inc., Alnylam Pharmaceuticals Inc., Santaris Pharma A/S, Exiqon A/S, AstraZeneca Pharmaceuticals LP, Biogen Idec Inc., Eli Lilly and Co., Pfizer Inc., CBC Comprehensive Biomarker Center GmbH, F. Hoffman-La Roche, GlaxoSmithKline, Merck & Co. Inc., Novartis AG and Sigma-Aldrich. GlaxoSmithKline (GSK) has established collaboration with Regulus Therapeutics to develop and commercialize therapeutics targeting microRNA-122 for hepatitis C virus (HCV) infection.
- Biogenesis
- Cellular functions
- Non-coding RNAs
Related Conference of Micro RNA
21th World Congress on Tissue Engineering Regenerative Medicine and Stem Cell Research
16th International Conference on Human Genetics and Genetic Diseases
19th International Conference on Genomics & Pharmacogenomics
Micro RNA Conference Speakers
Recommended Sessions
- Bioinformatics in Genomics
- Biomarkers
- Cancer genomics
- Cell Biology
- Clinical Genomics
- Comparative Genomics
- Functional Genomics
- Future Trends in Genomics
- Gene Editing
- Genome Medicine
- Genomics
- Human Genomics
- Micro RNA
- Microbial Genomics
- Molecular Biology
- Next Generation Sequencing
- Pharmacogenomics
- Plant Genomics and Molecular Plant Sciences
- Proteomics
- Stem Cell Biology
- Structural Biology
Related Journals
Are you interested in
- Artificial Intelligence and Computational Biology in Regenerative Medicine - Stemgen 2026 (France)
- Biomaterials and Nanotechnology in Regenerative Medicine - Stemgen 2026 (France)
- Cancer Stem Cells and Oncology - Stemgen 2026 (France)
- Cardiovascular Regeneration - Stemgen 2026 (France)
- Clinical Trials and Translational Stem Cell Research - Stemgen 2026 (France)
- Ethical, Legal, and Social Implications in Stem Cell Research - Stemgen 2026 (France)
- Future Trends: Organoids, Bioengineering, and Next-Generation Therapies - Stemgen 2026 (France)
- Gene Editing and CRISPR Technologies - Stemgen 2026 (France)
- Induced Pluripotent Stem Cells (iPSCs) and Reprogramming - Stemgen 2026 (France)
- Mesenchymal Stem Cells (MSCs) in Therapy - Stemgen 2026 (France)
- Regenerative Dentistry and Craniofacial Applications - Stemgen 2026 (France)
- Regenerative Medicine and Tissue Engineering - Stemgen 2026 (France)
- Stem Cell Banking and Cryopreservation - Stemgen 2026 (France)
- Stem Cell Biology and Cellular Mechanisms - Stemgen 2026 (France)
- Stem Cells in Neurological and Neurodegenerative Disorders - Stemgen 2026 (France)
